22:53:52 EDT Tue 16 Apr 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

News for U:AZN from 2023-04-17 to 2024-04-16 - 77 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-16 07:00U:AZNNews ReleaseIMFINZI(TM) (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
2024-04-11 07:00U:AZNNews ReleaseFASENRA approved for treatment of children aged 6 to 11 with severe asthma
2024-04-05 23:10U:AZNNews ReleaseENHERTU(TM) Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
2024-04-05 21:43U:AZNNews ReleaseENHERTU(TM) (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors
2024-04-05 07:00U:AZNNews ReleaseIMFINZI(TM) (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
2024-04-02 07:00U:AZNNews ReleaseDatopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
2024-04-01 07:00U:AZNNews ReleaseVOYDEYA(TM) approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH
2024-03-25 07:00U:AZNNews ReleaseULTOMIRIS(TM) (ravulizumab-cwvz) approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)
2024-03-19 07:00U:AZNNews ReleaseAstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer
2024-03-18 07:00U:AZNNews ReleaseAstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio
2024-03-13 07:06U:AZNNews ReleaseAstraZeneca announces initiation of THARROS - a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPD
2024-02-26 09:00U:AZNNews ReleaseAlexion Canada Raises Awareness for Rare Diseases Through International colourUp4RARE Campaign
2024-02-23 13:23U:AZNNews ReleaseMANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA
2024-02-19 07:10U:AZNNews ReleaseDatopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer
2024-02-19 07:05U:AZNNews ReleaseTAGRISSO ‚ ® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial
2024-02-19 02:00U:AZNNews ReleaseDatopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
2024-02-16 22:00U:AZNNews ReleaseTAGRISSO ‚ ® (osimertinib) with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer
2024-02-08 02:03U:AZNNews ReleaseAstraZeneca Full year and Q4 2023 Financial Results
2024-02-07 06:51U:AZNNews ReleaseSOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain
2024-02-06 09:00U:AZNNews ReleaseAstraZeneca expands US manufacturing footprint to accelerate ambitions in next-generation cell therapy discovery and development
2024-02-05 09:00U:AZNNews ReleaseYiviva Announces Memorandum of Understanding with AstraZeneca to Develop Platforms, Technologies, and Innovative Therapeutics through a Systems Biology Approach
2024-01-29 07:00U:AZNNews ReleaseENHERTU ‚ ® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with metastatic HER2-positive solid tumors
2024-01-22 07:00U:AZNNews ReleaseAIRSUPRA ‚ ® (albuterol/budesonide) now available as the first and only FDA-approved anti-inflammatory rescue option for asthma
2024-01-19 10:05U:AZNNews ReleaseIMFINZI ‚ ® (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization
2024-01-08 07:05U:AZNNews ReleaseCompugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
2024-01-02 09:00U:AZNNews ReleaseAllorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca
2023-12-26 02:01U:AZNNews ReleaseAstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases
2023-12-21 19:13U:AZNNews ReleaseWAINUA ¢ „ ¢ (eplontersen) Granted First-Ever Regulatory Approval in the US for the Treatment of Adults With Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
2023-12-19 07:10U:AZNNews ReleaseCompugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
2023-12-12 07:00U:AZNNews ReleaseAstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data
2023-12-10 19:35U:AZNNews ReleaseLong-term ALPHA Phase III trial data showed danicopan as add-on to ULTOMIRIS ‚ ® or SOLIRIS ‚ ® sustained clinical improvements in subset of patients with PNH experiencing clinically significant extravascular hemolysis
2023-11-30 08:00U:AZNNews ReleasePresage Biosciences Announces New Pharma Partnership to Evaluate Novel Immuno-Oncology Drug Combinations with CIVO ‚ ® Technology
2023-11-29 07:00U:AZNNews ReleaseAstraZeneca advances scientific leadership in hematology at ASH 2023
2023-11-20 08:27U:AZNNews ReleaseAstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes
2023-11-17 07:00U:AZNNews ReleaseTRUQAP ¢ „ ¢ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancer
2023-11-09 07:00U:AZNNews ReleaseIMFINZI ‚ ® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial
2023-11-08 07:00U:AZNNews ReleaseAstraZeneca to leverage its global industrial-scale manufacturing and digital capabilities to boost US renewable natural gas productivity
2023-11-03 11:30U:AZNNews ReleaseZibotentan/dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria in ZENITH-CKD Phase IIb trial
2023-11-01 07:00U:AZNNews ReleaseHealth Canada approves Ultomiris for adults with neuromyelitis optica spectrum disorder (NMOSD)
2023-10-24 07:00U:AZNNews ReleaseUS Food and Drug Administration accepts for review AstraZeneca ¢ € ™s Supplemental Biologics License Application for self-administration of FLUMIST ‚ ® QUADRIVALENT (Influenza Vaccine Live, Intranasal)
2023-10-24 07:00U:AZNNews ReleaseAlexion, AstraZeneca Rare Disease, concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria or atypical hemolytic uremic syndrome
2023-10-23 10:56U:AZNNews ReleaseDatopotamab deruxtecan improved progression-free survival vs. chemotherapy in patients with previously treated non-small cell lung cancer in TROPION-Lung01 Phase III trial
2023-10-23 10:50U:AZNNews ReleaseENHERTU ‚ ® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial
2023-10-23 10:30U:AZNNews ReleaseDatopotamab deruxtecan significantly extended progression-free survival vs. chemotherapy in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
2023-10-22 07:00U:AZNNews ReleaseDatopotamab deruxtecan plus IMFINZI ‚ ® (durvalumab) demonstrated robust and durable tumor responses in 1st-line treatment of patients with metastatic triple-negative breast cancer in BEGONIA Phase Ib/II trial
2023-10-18 09:00U:AZNNews ReleaseTogether for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry
2023-10-18 08:00U:AZNNews ReleaseSOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care
2023-10-18 08:00U:AZNNews ReleaseSOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care
2023-10-16 07:00U:AZNNews ReleaseTAGRISSO ‚ ® Plus Chemotherapy Granted Priority Review in the US for Patients with EGFR-Mutated Advanced Lung Cancer
2023-10-12 07:45U:AZNNews ReleaseFusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2068, a Novel Targeted Alpha Therapy for EGFR-cMET Expressing Cancers
2023-10-12 02:05U:AZNNews ReleaseAstraZeneca Awards Funding to Eight Innovative Research Projects From Early-Career Scientists Around the World in Second R&D Postdoctoral Challenge
2023-10-11 07:00U:AZNNews ReleaseAstraZeneca advances scientific leadership across multiple cancers with first data from four pivotal Phase III trials at ESMO
2023-10-10 10:30U:AZNNews ReleaseAstrazeneca Foundation Awards 12 Nonprofit Organizations More Than $2M to Advance Health Equity
2023-09-22 07:00U:AZNNews ReleaseDatopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
2023-09-14 02:00U:AZNNews ReleaseAstraZeneca advances UK clean heat and energy efficiencies with ‚ £100m commitment
2023-09-11 12:58U:AZNNews ReleaseFASENRA met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA)
2023-09-11 07:05U:AZNNews ReleaseTAGRISSO ‚ ® (osimertinib) Plus Chemotherapy Extended Median Progression-free Survival by Nearly 9 Months in EGFR-mutated Advanced Lung Cancer in FLAURA2 Phase III Trial
2023-09-11 07:00U:AZNNews ReleaseENHERTU ‚ ® (fam-trastuzumab deruxtecan-nxki) Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2-mutant Advanced Lung Cancer in DESTINY-Lung02 Phase II Trial
2023-08-25 07:10U:AZNNews ReleaseAstraZeneca urges re-examination of unintended consequences of Inflation Reduction Act on American cancer and rare disease patients
2023-08-16 10:00U:AZNNews ReleaseAstraZeneca Data at WCLC Advance Ambition to Have an AstraZeneca Medicine for More Than Half of All Patients Treated for Lung Cancer by 2030
2023-07-27 07:00U:AZNNews ReleaseENHERTU ‚ ® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial
2023-07-03 07:00U:AZNNews ReleaseDatopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients With Advanced Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial
2023-06-13 07:00U:AZNNews ReleaseAstraZeneca announces innovative partnership with Vanguard Renewables to decarbonize its United States sites
2023-06-12 07:00U:AZNNews ReleaseCapivasertib in combination with FASLODEX ‚ ® (fulvestrant) granted Priority Review in the US for patients with advanced HR-positive breast cancer
2023-06-05 08:05U:AZNNews ReleaseDatopotamab deruxtecan combinations showed encouraging tumor responses in patients with advanced non-small cell lung cancer in TROPION-Lung02 Phase Ib trial
2023-06-05 08:00U:AZNNews ReleaseENHERTU ‚ ® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable responses in patients across multiple HER2-expressing advanced solid tumors
2023-06-05 07:00U:AZNNews ReleaseANDEXXA Phase IV Trial Stopped Early After Achieving Pre-specified Criteria on Hemostatic Efficacy Versus Usual Care
2023-06-04 08:00U:AZNNews ReleaseTAGRISSO ‚ ® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial
2023-06-03 08:00U:AZNNews ReleaseLYNPARZA ‚ ® (olaparib) and IMFINZI ‚ ® (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemotherapy and bevacizumab in patients with advanced ovarian cancer without tumor BRCA mutations in the DUO-O Phase III trial
2023-06-02 15:56U:AZNNews ReleaseIMFINZI ‚ ® (durvalumab) plus chemotherapy significantly improved pathologic complete response in gastric and gastroesophageal junction cancers in MATTERHORN Phase III trial
2023-06-01 07:00U:AZNNews ReleaseLYNPARZA ‚ ® (olaparib) plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
2023-05-26 07:00U:AZNNews ReleaseIMFINZI ‚ ® (durvalumab) plus LYNPARZA ‚ ® (olaparib) and IMFINZI alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy
2023-05-25 07:00U:AZNNews ReleaseAstraZeneca will highlight momentum of practice-changing cancer medicines across its robust pipeline at ASCO 2023
2023-05-23 14:15U:AZNNews ReleaseNew AstraZeneca Data Presented at ATS 2023 Strengthen the Body of Evidence Supporting Early Intervention With BREZTRI in COPD
2023-05-09 11:37U:AZNNews ReleaseFARXIGA extended in the US to reduce risk of cardiovascular death and hospitalization for heart failure to a broader range of patients
2023-04-24 07:00U:AZNNews ReleaseNEURO-TTRansform Phase III results presented at AAN showed eplontersen demonstrated consistent and sustained improvement in all measures of disease and quality of life through 66 weeks
2023-04-17 16:15U:AZNNews ReleaseShanghai Cellular Biopharmaceutical Group presents first data from Phase I trial evaluating a novel CAR-T in advanced liver cancer at AACR Annual Meeting